Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) showed promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum-fluorouracil-cetuximab) in this setting. METHODS This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18-70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m2 was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m2 on day 1-4, cisplatin 100 mg/m2 on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m2 cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. FINDINGS Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34·4 months (IQR 26·6-44·8) in the TPEx group and 30·2 months (25·5-45·3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5-15·7] in the TPEx group and 13·4 months [12·2-15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74-1·08]; p=0·23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001). In the TPEx group, 118 (45%) of 263 patients had at least one serious adverse event versus 143 (54%) of 265 patients in the EXTREME group. 16 patients in the TPEx group and 21 in the EXTREME group died in association with adverse events, including seven patients in each group who had fatal infections (including febrile neutropenia). Eight deaths in the TPEx group and 11 deaths in the EXTREME group were assessed as treatment related, most frequently sepsis or septic shock (four in each treatment group). INTERPRETATION Although the trial did not meet its primary endpoint, with no significant improvement in overall survival with TPEx versus EXTREME, the TPEx regimen had a favourable safety profile. The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment. FUNDING Merck Santé and Chugai Pharma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32591-7 · Cited by 3,336
Self-citation
Cited by
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
Metadata
- Authors
- Guigay, J., Aupérin, A., Fayette, J., Saada-Bouzid, E., Lafond, C., Taberna, M., Geoffrois, L., Martin, L., Capitain, O., Cupissol, D., Castanie, H., Vansteene, D., Schafhausen, P., Johnson, A., Even, C., Sire, C., Duplomb, S., Evrard, C., Delord, J.-P., Laguerre, B., Zanetta, S., Chevassus-Clément, C., Fraslin, A., Louat, F., Sinigaglia, L., Keilholz, U., Bourhis, J., Mesia, R., BABA-HAMED, N., BABIN, E., BERA, G., BETRIAN-LAGARDE, S., BLOT, E., BOMPAS, E., BOREL, C., BOUCHEKOUA, M., BOZEC LE MOAL, L., BRUYAS, A., CALAIS, G., CARPIUC, I., CHAPET, S., CHATELLIER, T., CHAUFFERT, B., CHELI, S., CLATOT, F., COJOCARASU, O., CORNELLY, A., COUTTE, A., DALLOZ, P., DARLOY, F., DELHOMMEAU, M., DE RAUCOURT, D., DEBELLEIX, C., DEBOURDEAU, P., DILLIES-LEGRAIN, A. F., DO, P., DUBOS-ARVIS, C., DUCOULOMBIER, A., EL KOURI, C., FALKOWSKI, S., FERRAND, F.-R., GATINEAU, M., GERVAIS, R., GRAS, L., GUILLET, P., HASBINI, A., HENAULT, S., HERRERA GOMEZ, R. G., HUGUET, F., KAMINSKY, M. C., LAGRANGE, A., LAVAU-DENES, S., LE CAER, H., LE FOLL, C., LEFEBVRE, G., LINOT, B., LOPEZ, Q., LORTHOLARY, A., MATIAS, M., MAYACHE-BADIS, L., MINNE, F., MOLLON, D., NEIDHARDT, E. M., PAVILLET, J., PEYRADE, F., POINTREAU, Y., RAMEE, J.-F., RAUCHE, C., RICHARD, S., RIZZO, C., ROLLAND, F., SCHLURMANN, F., STEFANI, L., TASSY, L., TAZI, Y., THERY, J.-C., TORTI EL ZEIN, F., TOULLEC, C., TOURANI, J.-M., TOUSSAINT, P., VANBOCKSTAEL, J., VAULEON, E., VIRET, F., WALER, S., ATZPODIEN, J., BEHRENS, C., BUSCH, C. J., DIETZ, A., FELDMANN, G., FIETKAU, R., GRANIZKA, T., GREWE, J., GUNTINAS-LICHINUS, O., HADLER-MIKESCH, K., HAHN, D., INHESTERN, J., KELLNER, K., KLINGHAMMER, K., KRONENBERGER, R., LUEDTKE-HECKENKAMP, K., OCHSENREITHER, S., OTREMBA, B., PEUKER, C. A., PIRLICH, M., ROTHMANN, F., TOMETTEN, M., WOHLFARTH, S., ZEBRALLA, V., ZIPFEL, M., ADANSA KLEIN, J. C., ARRAZUBI, V., CABALLERO DAROQUI, J., CASTELO, B., CIRAUQUI CIRAUQUI, B., CRUZ HERNANDEZ, J. J., GALLEGO, O., IGLESIAS DOCAMPO, L. C., LOPEZ POUSA, A., MARTINEZ DEL PRADO, M., MARTINEZ-TRUFERO, J., PASTOR BORGONON, M., PEREZ RUIZ, E., QUIROGA GARCIA, V., RUBIO CASADEVALL, J., & VAZQUEZ FERNANDEZ, S.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 22
- Issue
- 4
- Pages
- 463-475
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3134959030
- Cited by
- 232
- References
- 1
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30755-5
- The paper
- Guigay, J., Aupérin, A., Fayette, J., Saada-Bouzid, E., Lafond, C., Taberna, M., Geoffrois, L., Martin, L., Capitain, O., Cupissol, D., Castanie, H., Vansteene, D., Schafhausen, P., Johnson, A., Even, C., Sire, C., Duplomb, S., Evrard, C., Delord, J.-P., . . . VAZQUEZ FERNANDEZ, S. (2021). Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30755-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.